Further, the combination treatment also showed synergistic activity in two other BRCA1/2 wild‐type ovarian cancer cell lines, OAW42 and A2780 (Figure S28A–D, Supporting Information). This evidence concerns the gene BRCA1 and ovarian carcinoma.